[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"insulin-resistance-diabetes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:insulin-resistance-diabetes":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,54],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":4},"100645319","diabetes-insulin-gut-enteric-supplementation-trial-100645319",false,"NCT07682077","Diabetes, Insulin, Gut, Enteric Supplementation Trial","Effects of a Kefir Intervention in Pregnancy on Glucose, Insulin, Gestational Diabetes Mellitus, and the Gut Microbiome and Metabolites: A Randomized Controlled Trial","DIGEST","Inclusion Criteria:\n\n* Pregnant individual with a singleton pregnancy\n* 19 years and older of age\n* Gestational age 14,3 weeks or less at enrolment\n* Able and willing to attend four in-person study visits at the PEADS Laboratory: baseline, 18-20 weeks' gestation, 26-28 weeks' gestation, and 1 month postpartum\n* Willing and able to comply with study group assignment, including daily consumption of 250 mL of kefir if assigned to the intervention group\n* Willing to avoid kefir consumption until completion of the 26-28-week study visit if assigned to the control group\n* Willing to provide required biological and clinical samples, including stool samples and glucose\u002Finsulin data, according to the study protocol\n* No probiotic, prebiotic, synbiotic, or antibiotic use during the first trimester or at enrollment\n* Not currently consuming probiotic, prebiotic, synbiotic, or antiobiotic supplements\n* Willing to avoid probiotic, prebiotic, and synbiotic supplements until completion of the 26-28-week study visit.\n* Does not engage in regular moderate-to-vigorous physical activity\n* No recent or active infectious illness or significant gastrointestinal symptoms, including diarrhea or constipation in the first trimester of pregnancy.\n* No history of bariatric surgery\n* Able to communicate in English or French\n* Currently living in Fredericton, New Brunswick, and not planning to relocate before the 1-month postpartum visit\n\nExclusion Criteria:\n\n* Pre-existing metabolic disease affecting glucose regulation, including type 1 diabetes or type 2 diabetes\n* Current use or first trimester use of medications known to alter glucose metabolism, such as metformin or semaglutide\n* Gastrointestinal or inflammatory disease, including Crohn's disease, ulcerative colitis, celiac disease, or diagnosed irritable bowel syndrome\n* Allergy, intolerance, or other contraindication to dairy or components of kefir",true,"FEMALE","19 Years",{"count":21,"type":22},60,"ESTIMATED","INTERVENTIONAL",[25],"NA","Pregnancy is a critical window for metabolic health, and early changes in blood sugar regulation can increase the risk of gestational diabetes mellitus (GDM), which affects both maternal and infant health. At the same time, the maternal gut microbiome changes throughout pregnancy and may play a role in glucose metabolism and insulin resistance. Kefir, a fermented milk drink containing beneficial bacteria and yeasts, may be a simple dietary strategy to support metabolic health during pregnancy, but its role in preventing GDM has not been well studied.\n\nThis study will test whether drinking kefir daily from mid-pregnancy until routine GDM screening can improve glucose and insulin regulation, reduce the incidence of GDM, and modulate the maternal gut microbiome and metabolites, among other outcomes.\n\nPregnant individuals will be randomly assigned to either a kefir group or a control group receiving usual prenatal care. Researchers will collect blood glucose and insulin measures, dietary information, stool samples, and body composition data across pregnancy and postpartum to evaluate metabolic and microbiome-related changes.\n\nAs one of the first studies to examine kefir as an early pregnancy intervention for GDM prevention, this study will help clarify whether a practical, food-based approach can improve maternal metabolic health. The findings may support future nutrition strategies aimed at reducing GDM risk and improving pregnancy outcomes.",[28,29,30,31,32],"Gestational Diabetes Mellitus (GDM)","Blood Glucose","Insulin Resistance, Diabetes","Gut Microbiome","Gut Metabolites",[34,35,36,37,38,39,40,41],"Gestational diabetes mellitus","Pregnancy","Probiotics","Kefir","Gut microbiome","Gut metabolites","Glucose","Insulin","NOT_YET_RECRUITING","2026-06-30",{"date":45,"type":46},"2026-07-02","ACTUAL",{"date":48,"type":22},"2026-06-01",{"date":50,"type":22},"2029-06-01",{"name":52,"class":53},"University of New Brunswick","OTHER",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":18,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":74,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":85},"100557792","studying-phenotypes-of-gestational-diabetes-mellitus-in-an-asian-pregnant-cohort-100557792","NCT06542718","Studying Phenotypes of Gestational Diabetes Mellitus in an Asian Pregnant Cohort","Studying the Heterogeneity of Gestational Diabetes Mellitus: Cardio-Metabolic Alteration and Treatment Response in a Multi-Ethnic Population in Singapore (GDM-CARE)","GDM-CARE","Inclusion Criteria:\n\n* Gestational age of ≤ 13 weeks 6 days\n* Overweight and obese subjects with BMI of 23kg\u002Fm² - 24.9kg\u002Fm² and ≥ 25.0kg\u002Fm², respectively\n* Aged 21-45 years with singleton pregnancy\n* Plan to be followed up during the whole pregnancy and deliver at NUH\n* Chinese, Malay or Indian ethnicity for pregnant subject\n* Can complete questionnaires in English language\n* Willing to wear continuous glucose monitoring device at least for 7 days at each required clinic visit\n\nExclusion Criteria:\n\n* Participants who are not Singapore citizens or Singapore Permanent Residents, not intending to eventually deliver in Singapore National University Hospital and to reside in Singapore for the next 2 years\n* Have serious skin conditions (eg. eczema) that precludes wearing the sensor for 14 days\n* With history of Type 1 diabetes or Type 2 diabetes\n* With chronic preexisting life-threatening conditions including pancreatic cancer, end-stage kidney dysfunction, and psychosis\n* Unable to read or speak English","21 Years","45 Years",{"count":65,"type":22},800,"OBSERVATIONAL","Gestational diabetes mellitus (GDM) is a transient hyperglycemic condition identified during pregnancy in women without a history of chronic diabetes. Evidence indicates that GDM can lead to various adverse health outcomes, including preterm birth, progression to pre-diabetes, and type 2 diabetes after delivery in mothers. Notably, GDM is becoming increasingly prevalent among Asian pregnant women due to rising rates of overweight and obesity, as well as genetic susceptibility. Despite growing recognition of GDM, its treatment efficiency and efficacy remain poor, primarily due to its heterogeneity, which is underpinned by various pathophysiological mechanisms.\n\nTherefore, a better understanding of GDM heterogeneity can aid clinicians in providing more targeted treatment and follow-up strategies for GDM mothers. This study aims to define GDM phenotypes based on in vivo cardio-metabolic profiles and treatment response during pregnancy, utilizing advanced technologies such as continuous glucose profiling and untargeted metabolite profiling. In this proposed 3-year pregnancy cohort study, the investigators will recruit 800 overweight or obese Asian pregnant women in early pregnancy, without a history of diabetes, and follow them through to delivery. The goal of the study is to develop systematic antenatal and postnatal screening, treatment, and intervention guidelines for mothers with GDM.",[69,70,71,72,30,73],"Gestational Diabetes","Pregnancy Related","Pregnancy Complications","Birth Weight","Intergenerational Relations",[35],"RECRUITING","2025-05-25",{"date":78,"type":46},"2025-05-28",{"date":80,"type":46},"2022-10-03",{"date":82,"type":22},"2026-07-01",{"name":84,"class":53},"National University Health System, Singapore",1]